Iloperidone, asenapine and lurasidone: A primer on their current status

Expert Opinion on Pharmacotherapy

Volumn 13, Issue 13, 2012, Pages 1911-1922

  Tarazi, Frank I ^a   Stahl, Stephen M ^b,c  

^a MCLEAN HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Antipsychotic drugs; Bipolar disorder; Clinical trials; Depression; Receptor pharmacology; Safety and tolerability; Schizophrenia

Indexed keywords

ASENAPINE; CIPROFLOXACIN; CYTOCHROME P450 1A2; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DILTIAZEM; DRUG METABOLITE; DULOXETINE; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; ILOPERIDONE; KETOCONAZOLE; LITHIUM; LURASIDONE; NEFAZODONE; NEUROTRANSMITTER RECEPTOR; OLANZAPINE; PAROXETINE; PLACEBO; QUETIAPINE; QUINIDINE; RIFAMPICIN; RISPERIDONE; VALPROIC ACID; VERAPAMIL; ZIPRASIDONE;

ACUTE DISEASE; ADJUVANT THERAPY; AKATHISIA; AVOIDANCE BEHAVIOR; BILIARY EXCRETION; BIPOLAR I DISORDER; BIPOLAR MANIA; BRIEF PSYCHIATRIC RATING SCALE; DIZZINESS; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DYSTONIA; FATIGUE; FOOD AND DRUG ADMINISTRATION; GENETIC MARKER; HUMAN; HYPERPROLACTINEMIA; HYPESTHESIA; LONG TERM CARE; LOW DRUG DOSE; MAINTENANCE CHEMOTHERAPY; MANIA; MENTAL PATIENT; NAUSEA; NEGATIVE SYNDROME; NONHUMAN; OPEN STUDY; ORAL DYSESTHESIA; ORTHOSTATIC HYPOTENSION; OUTCOME ASSESSMENT; PARKINSONISM; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSITIVE AND NEGATIVE SYNDROME SCALE; POST HOC ANALYSIS; PREDICTION; PUBLICATION; RECEPTOR AFFINITY; RELAPSE; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SINGLE DRUG DOSE; SINGLE NUCLEOTIDE POLYMORPHISM; SOMNOLENCE; SYNCOPE; TABLET FORMULATION; TACHYCARDIA; WEIGHT GAIN; YOUNG MANIA RATING SCALE;

ADULT; ANIMALS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DRUG APPROVAL; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; HUMANS; ISOINDOLES; ISOXAZOLES; PIPERIDINES; SCHIZOPHRENIA; THIAZOLES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84865318995     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2012.712114     Document Type: Review

References (86)

1. Heckers S, Berretta S. Schizophrenia. In: Tarazi FI, Schetz JA, editors. Neurological and psychiatric disorders: from bench to bedside. Humana Press; Totowa, NJ: 2005. p. 111-29
2. Awad AG, Voruganti LN. The burden of schizophrenia on caregivers: a review. Pharmacoeconomics 2008;26:149-62
3. O'Carroll R. Cognitive impairment in schizophrenia. Adv Psychiatr Treat 2000;6:161-8
4. Baldessarini RJ, Tarazi FI. Pharmacotherapy of psychosis and mania. In: Brunton LL, Lazo JS, Parker KL, editors. Goodman and Gilman's the pharmacological basis of therapeutics. 11th edition. McGraw-Hill; New York: 2005. p. 461-500
5. Stahl SM. Stahl's essential psychopharmacology. 3rd edition. Cambridge Univ Press; NY: 2008
6. Stahl SM. Stahl's essential psychopharmacology: the prescribers guide. 4th edition. Cambridge University Press; NY: 2011
7. Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789-96
8. Meltzer HY. Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology (Berl) 1989;99(Suppl):S18-27 (Pubitemid 19244134)
9. Baldessarini RJ, Frankenburg FR. Clozapine. A novel antipsychotic agent. N Engl J Med 1991;324:746-54
10. Brunello N, Masotto C, Steardo L, et al. New insights into the biology of schizophrenia through the mechanism of action of clozapine. Neuropsychopharmacology 1995;13:177-213
11. Raja M. Clozapine safety, 35 years later. Curr Drug Saf 2011;6:164-84
12. Leung JY, Barr AM, Procyshyn RM, et al. Cardiovascular side-effects of antipsychotic drugs: the role of the autonomic nervous system. Pharmacol Ther 2012;135:113-22
13. Tarsy D, Baldessarini RJ, Tarazi FI. Effects of newer antipsychotics on extrapyramidal function. CNS Drugs 2002;16:23-45
14. Leucht S, Tardy M, Komossa K, et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet 2012;379:2063-71
15. Rege S. Antipsychotic induced weight gain in schizophrenia: mechanisms and management. Aust NZ J Psychiatry 2008;42:369-81 (Pubitemid 351877210)
16. Nasrallah HA. Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry 2008;13:27-35 (Pubitemid 350275185)
17. Meyer JM, Stahl SM. The metabolic syndrome and schizophrenia. Acta Psychiatr Scand 2009;119:4-14
18. Stahl SM, Mignon L, Meyer JM. Which comes first: atypical antipsychotic treatment or cardiometabolic risk? Acta Psychiatr Scand 2009;119:171-9
19. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-23 (Pubitemid 41345943)
20. Jones PB, Barnes TR, Davies L, et al. Randomized controlled trial of the effect on quality of life of second-vs first-generation antipsychotic drugs in schizophrenia: cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 2006;63:1079-87 (Pubitemid 44498387)
21. Kongsamut S, Roehr JE, Cai J, et al. Iloperidone binding to human and rat dopamine and 5-HT receptors. Eur J Pharmacol 1996;317:417-23 (Pubitemid 27014051)
22. Richelson E, Souder T. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci 2000;68:29-39
23. Kalkman HO, Subramanian N, Hoyer D. Extended radioligand binding profile of iloperidone: a broad spectrum dopamine/serotonin/norepinephrine receptor antagonist for the management of psychotic disorders. Neuropsychopharmacology 2001;25:904-14 (Pubitemid 34031895)
24. Barr AM, Powell SB, Markou A, et al. Iloperidone reduces sensorimotor gating deficits in pharmacological models, but not a developmental model, of disrupted prepulse inhibition in rats. Neuropharmacology 2006;51:457-65 (Pubitemid 44215953)
25. Volpi S, Potkin SG, Malhotra AK, et al. Applicability of a genetic signature for enhanced iloperidone efficacy in the treatment of schizophrenia. J Clin Psychiatry 2009;70(6):801-9
26. Shahid M, Walker GB, Zorn SH, et al. Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol 2009;23:65-73
27. Ghanbari R, El Mansari M, Shahid M, et al. Electrophysiological characterization of the effects of asenapine at 5-HT1A, 5-HT2A, alpha2-adrenergic and D2 receptors in the rat brain. Eur Neuropsychopharmacol 2009;19:177-87
28. Frånberg O, Wiker C, Marcus MM, et al. Asenapine, a novel psychopharmacologic agent: preclinical evidence for clinical effects in schizophrenia. Psychopharmacology (Berl) 2008;196:417-29 (Pubitemid 351200428)
29. Marston HM, Young JW, Martin FD. Asenapine effects in animal models of psychosis and cognitive function. Psychopharmacology (Berl) 2009;206:699-714
30. Snigdha S, Idris N, Grayson B, et al. Asenapine improves phencyclidine-induced object recognition deficits in the rat: evidence for engagement of a dopamine D1 receptor mechanism. Psychopharmacology (Berl) 2011;214:843-53
31. Elsworth JD, Groman SM, Jentsch JD, et al. Asenapine effects on cognitive and monoamine dysfunction elicited by subchronic phencyclidine administration. Neuropharmacology 2012;62:1442-52
32. Frånberg O, Marcus MM, Ivanov V, et al. Asenapine elevates cortical dopamine, noradrenaline and serotonin release. Evidence for activation of cortical and subcortical dopamine systems by different mechanisms. Psychopharmacology (Berl) 2009;204:251-64
33. Huang M, Li Z, Dai J, et al. Asenapine increases dopamine, norepinephrine, and acetylcholine efflux in the rat medial prefrontal cortex and hippocampus. Neuropsychopharmacology 2008;33:2934-45
34. Tarazi FI, Moran-Gates T, Wong EH, et al. Differential regional and dose-related effects of asenapine on dopamine receptor subtypes. Psychopharmacology (Berl) 2008;198:103-11
35. Tarazi FI, Choi YK, Gardner M, et al. Asenapine exerts distinctive regional effects on ionotropic glutamate receptor subtypes in rat brain. Synapse 2009;63:413-20
36. Tarazi FI, Moran-Gates T, Wong EH, et al. Asenapine induces differential regional effects on serotonin receptor subtypes. J Psychopharmacol 2010;24:341-8
37. Choi YK, Wong EH, Henry B, et al. Repeated effects of asenapine on adrenergic and cholinergic muscarinic receptors. Int J Neuropsychopharmacol 2010;13:405-10
38. Ishibashi T, Horisawa T, Tokuda K, et al. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. J Pharmacol Exp Ther 2010;334:171-81
39. Albers LJ, Musenga A, Raggi MA. Iloperidone: a new benzisoxazole atypical antipsychotic drug. Is it novel enough to impact the crowded atypical antipsychotic market? Expert Opin Investig Drugs 2008;17:61-75 (Pubitemid 351578211)
40. Jain KK. An assessment of iloperidone for the treatment of schizophrenia. Expert Opin Investig Drugs 2000;9:2935-43
41. Subramanian N, Kalkman HO. Receptor profile of P88-8991 and P95-12113, metabolites of the novel antipsychotic iloperidone. Prog Neuropsychopharmacol Biol Psychiatry 2002;26:553-60 (Pubitemid 34252950)
42. Stahl SM. Iloperidone. In: Stahl SM, editor. Stahl's essential psychopharmacology: the prescribers guide. 4th edition. Cambridge University Press; NY: 2011. p. 267-71
43. Sedek G, Wolfgang CD. Iloperidone is well tolerated by subjects with renal or hepatic impairment in single-dose clinical pharmacokinetic studies. Presented at American Psychiatric Association Annual Meeting; 27 May 2007; San Diego, CA
44. Product Information Saphris® (asenapine) sublingual tablets. Initial US approval: 2009
45. Tarazi FI, Shahid M. Asenapine maleate: a new drug for the treatment of schizophrenia and bipolar mania. Drugs Today 2009;45:865-76
46. Stahl SM. Asenapine. In: Stahl SM, editor. Stahl's essential psychopharmacology: the prescribers guide. 4th edition. Cambridge University Press; NY: 2011b. p. 59-63
47. Peeters PAM, Bockbrader H, Spaans E, et al. Asenapine pharmacokinetics: influence of hepatic and renal impairment [abstract NR4-081]. 161st Amer Psychiatric Assoc; 3-8 May, Washington DC; 2008
48. Product Information Latuda® (lurasidone). Initial US approval: 2010
49. Chiu YY, Preskorn S, Sarubbi D, et al. Effect of food on lurasidone absorption (Poster). Presented at the NCDEU meeting; Boca Raton, FL; 2010
50. Meyer JM, Loebel AD, Schweizer E. Lurasidone: a new drug in development for schizophrenia. Expert Opin Investig Drugs 2009;18:1715-26
51. Stahl SM. Lurasidone. In: Stahl SM, editor. Stahl's essential psychopharmacology: the prescribers guide. 4th edition. Cambridge University Press; NY: 2011. p. 337-42
52. Product Information Fanapt® (iloperidone). Initial US approval: 2009
53. Citrome L. Iloperidone for schizophrenia: a review of the efficacy and safety profile for this newly commercialized second-generation antipsychotic. Int J Clin Pract 2009;63:1237-48
54. Sonovion News Release. Latuda® (Lurasidone HCl) updated with expanded dosing range providing added flexibility for the treatment of patients with schizophrenia. May 5, 2012
55. Corbett R, Griffiths L, Shipley JE. Iloperidone: preclinical profile and early clinical evaluation. CNS Drug Rev 1997;3:120-47 (Pubitemid 27509410)
56. Potkin SG, Litman RE, Torres R, et al. Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studies. J Clin Psychopharmacol 2008;28(2 Suppl 1):S4-11
57. Cutler AJ, Kalali AH, Weiden PJ, et al. Four-week, double-blind, placebo-and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia. J Clin Psychopharmacol 2008;28(2 Suppl 1):S20-8 (Pubitemid 351397673)
58. Citrome L, Meng X, Hochfeld M, et al. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo-and active-controlled trials. Hum Psychopharmacol 2012;27:24-32
59. Kane JM, Lauriello J, Laska E, et al. Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia. J Clin Psychopharmacol 2008;28(2 Suppl 1):S29-35 (Pubitemid 351397674)
60. Potkin SG, Cohen M, Panagides J. Efficacy and tolerability of asenapine in acute schizophrenia: a placebo-and risperidone-controlled trial. J Clin Psychiatry 2007;68:1492-500 (Pubitemid 350073395)
61. Kane JM, Zhao J, Cohen M, et al. Efficacy and safety of asenapine in patients with acute schizophrenia [abstract 290]. 23rd Amer Psychiatric Nurses Assoc; 7-10 October; Charleston, SC; 2009
62. Mackle M, Snow-Adami L, Zhao J, et al. Double-blind placebo-controlled trial of asenapine in prevention of relapse after long-term treatment of schizophrenia [abstract P.3.c.057]. 22nd Cong Eur Coll Neuropsychopharmacol; 12-16 September; Istanbul, Turkey; 2009
63. Buchanan RW, Panagides J, Zhao J, et al. Asenapine versus olanzapine in people with persistent negative symptoms of schizophrenia. J Clin Psychopharmacol 2012;32:36-45
64. McIntyre RS, Alphs L, Cohen M, et al. Treatment of mania in bipolar I disorder: placebo-and olanzapine-controlled trials of asenapine [abstract P2.e.012]. 20th Congr Eur Coll Neuropsychopharmacol; 13-17 October; Vienna, Austria; 2007
65. McIntyre RS, Panagides J, Alphs L, et al. Asenapine in acute mania: a randomized, double-blind, placebo-and olanzapine-controlled trial (ARES 7501004). Biol Psychiatry 2007;61(S 8):S222-3
66. McIntyre RS, Cohen M, Zhao J, et al. A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states. Bipolar Disord 2009;11:673-86
67. Szegedi A, Calabrese JR, Stet L, et al. Asenapine as adjunctive treatment for acute mania associated with bipolar disorder: results of a 12-week core study and 40-week extension. J Clin Psychopharmacol 2012;32:46-55
68. Ogasa M, Boylan M, Phillips D, et al. Efficacy of lurasidone (SM-13496) in the treatment of schizophrenia: results of two phase 2, placebo-conrolled studies. Eur Neuropsychopharmacol 2005;15:S522-3
69. Phillips D, Ogasa M, Severs J, et al. Efficacy of lurasidone in schizophrenia: results of a phase 2, placebo-controlled study. Schizophr Bull 2007;33:572-3
70. Loebel A, Cucchiaro J, Ogasa M. Efficacy of lurasidone in schizophrenia: summary of results from the clinical development program. Int J Neuropsychopharmacol 2010;13(Suppl 1):217
71. Meltzer HY, Cucchiaro J, Silva R, et al. Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo-and olanzapine-controlled Study. Am J Psychiatry 2011;168:957-67
72. Loebel A, Cucchiaro J, Sarma K, et al. Lurasidone in the treatment of acute schizophrenia: Results of the double-blind, placebo-controlled, 6-week, Pearl 3 trial [abstract no NR6-38]. 164th Annual Meeting of the American Psychiatric Association; 14-18 May 2011; Honolulu, HA
73. Weiden PJ, Cutler AJ, Polymeropoulos MH, Wolfgang CD. Safety profile of iloperidone: a pooled analysis of 6-week acute-phase pivotal trials. J Clin Psychopharmacol 2008;28(2 Suppl 1):S12-19 (Pubitemid 351397672)
74. Nakamura M, Ogasa M, Guarino J, et al. Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial. J Clin Psychiatry 2009;70:829-36
75. Chapel S, Hutmatcher M, Haig G, et al. Exposure-response analysis in patients with schizophrenia to assess the effect of asenapine, quetiapine, or placebo administration on QTc prolongation. J Clin Psychopharmacol 2009;49:1297-308
76. Citrome L. Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic. Int J Clin Pract 2011;65:189-210
77. Loebel A, Cucchiaro J, Xu J, et al. Effectiveness of lurasidone vs. quetiapine XR for relapse prevention in schizophrenia: A 12-month, double-blind study [abstract no NR6-36]. 165th Annual Meeting of the American Psychiatric Association; 5-9 May 2012; Philadelphia, PA
78. Millan MJ. Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies. Therapie 2005;60:441-60
79. Mnie-Filali O, Faure C, Lambás-Señas L, et al. Pharmacological blockade of 5-HT7 receptors as a putative fast acting antidepressant strategy. Neuropsychopharmacology 2011;36:1275-88
80. Loebel A, Cucchiaro J, Silva R, et al. Lurasidone monotherapy for the treatment of bipolar I depression: Results of a 6-week, double-blind, placebo-controlled study [abstract no NR4-58]. 165th Annual Meeting of the American Psychiatric Association; 5-9 May 2012; Philadelphia, PA
81. Carney RM, Shelton RC. Agomelatine for the treatment of major depressive disorder. Expert Opin Pharmacother 2011;12:2411-19
82. Akimova E, Lanzenberger R, Kasper S. The serotonin-1A receptor in anxiety disorders. Biol Psychiatry 2009;66:627-35
83. Savitz J, Lucki I, Drevets WC. 5-HT1A receptor function in major depressive disorder. Prog Neurobiol 2009;88:17-31
84. Shelton RC, Osuntokun O, Heinloth AN, et al. Therapeutic options for treatment-resistant depression. CNS Drugs 2010;24:131-61
85. Shelton RC, Tollefson GD, Tohen M, et al. Novel augmentation strategy for treating resistant major depression. Am J Psychiatry 2001;158:131-4 (Pubitemid 32047260)
86. Stahl SM. Selective histamine H1 antagonism: novel hypnotic and pharmacologic actions challenge classical notions of antihistamines. CNS Spectr 2008;13:1027-38:1969-1983